Eli Lilly

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Eli Lilly 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About LLY

Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products include diabetes, oncology, immunology, neuroscience, and other products and therapies. 

CEO
David A. Ricks
CEODavid A. Ricks
Employees
50,000
Employees50,000
Headquarters
Indianapolis, Indiana
HeadquartersIndianapolis, Indiana
Founded
1876
Founded1876
Employees
50,000
Employees50,000

LLY Key Statistics

Market cap
1.19T
Market cap1.19T
Price-Earnings ratio
42.09
Price-Earnings ratio42.09
Dividend yield
0.55%
Dividend yield0.55%
Average volume
2.23M
Average volume2.23M
High today
$1,227.79
High today$1,227.79
Low today
$1,211.01
Low today$1,211.01
Open price
$1,215.18
Open price$1,215.18
Volume
423.43K
Volume423.43K
52 Week high
$1,249.45
52 Week high$1,249.45
52 Week low
$623.78
52 Week low$623.78

Stock Snapshot

As of today, Eli Lilly(LLY) shares are valued at $1,221.72. The company's market cap stands at 1.19T, with a P/E ratio of 42.09 and a dividend yield of 0.55%.

During the trading session on 2026-07-29, Eli Lilly(LLY) shares reached a daily high of $1,227.79 and a low of $1,211.01. At a current price of $1,221.72, the stock is +0.9% higher than the low and still -0.5% under the high.

Trading volume for Eli Lilly(LLY) stock has reached 423.43K, versus its average volume of 2.23M.

The stock's 52-week range extends from a low of $623.78 to a high of $1,249.45.

The stock's 52-week range extends from a low of $623.78 to a high of $1,249.45.

LLY News

Investing.com 37m
Eli Lilly stock may move 6.9% on Aug. 5 earnings report - Investing.com

...

Eli Lilly stock may move 6.9% on Aug. 5 earnings report - Investing.com
Nasdaq 3h
Watch Out, Eli Lilly and Novo Nordisk: Amgen's Monthly Weight Loss Drug Has 6 Phase 3 Trials Running -- and It's Coming for Your Patients

Key Points Amgen wants a slice of the weight loss drug market. Its candidate for capturing that market share might not be up to the task. Its competitors are...

Watch Out, Eli Lilly and Novo Nordisk: Amgen's Monthly Weight Loss Drug Has 6 Phase 3 Trials Running -- and It's Coming for Your Patients
Nasdaq 3h
Johnson & Johnson vs. Eli Lilly: Reliable Stability vs. Rapid Revenue Growth

Key Points Eli Lilly currently displays stronger upward momentum in top-line growth, whereas Johnson & Johnson maintains a higher but flatter overall baseline....

Johnson & Johnson vs. Eli Lilly: Reliable Stability vs. Rapid Revenue Growth

Analyst ratings

81%

of 31 ratings
Buy
80.6%
Hold
12.9%
Sell
6.5%

More LLY News

Nasdaq 5h
Eli Lilly Is Acquiring AtaiBeckley for $2.8 Billion. Cathie Wood Thinks Another Psychedelic Drug Stock Is an Even Better Bet.

Key Points One of Cathie Wood's funds just sold some AtaiBeckley shares. It also bought some Compass Pathways shares. This move makes total sense given that...

Eli Lilly Is Acquiring AtaiBeckley for $2.8 Billion. Cathie Wood Thinks Another Psychedelic Drug Stock Is an Even Better Bet.
Simply Wall St 9h
GH Research Stock Looks Stretched On Its 111% YTD Run

GH Research stock has surged 111.2% year to date, yet its valuation checks indicate the shares do not screen as a clear bargain. Investors are weighing that str...

GH Research Stock Looks Stretched On Its 111% YTD Run
Nasdaq 22h
Eli Lilly Just Made a $2.8 Billion Bet That Goes Beyond GLP-1 Drugs

Key Points Eli Lilly's newest acquisition will expand its neuroscience portfolio. The company is bracing for stiff competition within its core therapeutic are...

Eli Lilly Just Made a $2.8 Billion Bet That Goes Beyond GLP-1 Drugs
TipRanks 23h
Goldman Sachs Forecasts Weak Obesity Pill Sales from Eli Lilly

Wall Street investment bank Goldman Sachs (GS) is bucking consensus, forecasting weak sales of Eli Lilly’s (LLY) new weight-loss pill when the company reports e...

Simply Wall St 1d
How Illumina’s Billion Cell Atlas Expansion Could Reshape Eli Lilly’s Drug Discovery Edge

In July 2026, Illumina announced that its Billion Cell Atlas alliance, originally launched with AstraZeneca, Merck, and Eli Lilly, had expanded to include three...

How Illumina’s Billion Cell Atlas Expansion Could Reshape Eli Lilly’s Drug Discovery Edge
Simply Wall St 3d
Eli Lilly Could Be 19% Undervalued After Novo Nordisk Lawsuit

Novo Nordisk’s lawsuit over obesity and diabetes drug advertising has pulled Eli Lilly (LLY) further into the spotlight and raised fresh questions about how thi...

Eli Lilly Could Be 19% Undervalued After Novo Nordisk Lawsuit
The Motley Fool 5d
Why Is Novo Nordisk Suing Eli Lilly, and What Does it Mean for Investors?

GLP-1 drugs for weight loss are such a booming business that it was inevitable the major manufacturers of these wonder drugs would eventually end up in court. T...

Why Is Novo Nordisk Suing Eli Lilly, and What Does it Mean for Investors?

People also own

Based on the portfolios of people who own LLY. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.